Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment

Nature Communications

Volumn 5, Issue , 2014, Pages

  Liu, Ze ^a   Xiong, Min ^a   Gong, Junbo ^b   Zhang, Yan ^a   Bai, Nan ^a   Luo, Yunping ^c   Li, Luyuan ^a   Wei, Yuquan ^d   Liu, Yanhua ^a   Tan, Xiaoyue ^a   Xiang, Rong ^a  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

^c Beijing Union Medical School   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINE; CELL PENETRATING PEPTIDE; DOXORUBICIN; LEGUMAIN; LIPOSOME; ANTINEOPLASTIC ANTIBIOTIC; CYSTEINE PROTEINASE; NANOPARTICLE; TRANSACTIVATOR PROTEIN;

CANCER; CATALYSIS; ENZYME ACTIVITY; LEGUME; MEMBRANE; PEPTIDE; TOXICITY; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; TUMOR MICROENVIRONMENT; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; DOXORUBICIN; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MICE; NANOPARTICLES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903625230     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5280     Document Type: Article

References (42)

1. Deng, Z. J. et al. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and sirna for potential triple-negative breast cancer treatment. ACS Nano 7, 9571-9584 (2013
2. Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583-592 (2006 (Pubitemid 44140857)
3. Haag, R. Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew. Chem. Int. Ed. 43, 278-282 (2004 (Pubitemid 38090059)
4. Najer, A., Wu, D., Vasquez, D., Palivan, C. G. & Meier, W. Polymer nanocompartments in broad-spectrum medical applications. Nanomedicine (Lond) 8, 425-447 (2013
5. Zhang, Y., Wang, Z. & Gemeinhart, R. A. Progress in microRNA delivery. J. Control. Release 172, 962-974 (2013
6. Perche, F. & Torchilin, V. P. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J. Drug Deliv. 2013, 705265 (2013
7. Koren, E. & Torchilin, V. P. Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med. 18, 385-393 (2012
8. Qin, Y. et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int. J. Pharm. 420, 304-312 (2011
9. Vives, E., Schmidt, J. & Pelegrin, A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta. 1786, 126-138 (2008
10. Takara, K. et al. Size-controlled dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J. Control. Release 162, 225-232 (2012
11. Kibria, G., Hatakeyama, H. & Harashima, H. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. Int. J. Pharm. 412, 106-114 (2011
12. Tagalakis, A. D. et al. Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. Biomaterials 32, 1370-1376 (2011
13. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
14. Reisfeld, R. A. The tumor microenvironment: a target for combination therapy of breast cancer. Crit. Rev. Oncog. 18, 115-133 (2013
15. Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013
16. Lin, Y. et al. Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis. Cancer Sci. 104, 1217-1225 (2013
17. Luo, Y. et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116, 2132-2141 (2006 (Pubitemid 44162322)
18. Lewen, S. et al. A legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol. Immunother. 57, 507-515 (2008 (Pubitemid 351170534)
19. Xiang, R., Luo, Y., Niethammer, A. G. & Reisfeld, R. A. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol. Rev. 222, 117-128 (2008 (Pubitemid 351430375)
20. Dall, E. & Brandstetter, H. Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation. Proc. Natl Acad. Sci. USA 110, 10940-10945 (2013
21. Miller, G., Matthews, S. P., Reinheckel, T., Fleming, S. & Watts, C. Asparagine endopeptidase is required for normal kidney physiology and homeostasis. FASEB J. 25, 1606-1617 (2011
22. Liu, C., Sun, C., Huang, H., Janda, K. & Edgington, T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63, 2957-2964 (2003 (Pubitemid 36667169)
23. Chen, Y. J. et al. Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection. Biomaterials 35, 304-315 (2013
24. Li, N. et al. Effects of legumain as a potential prognostic factor on gastric cancers. Med. Oncol. 30, 621 (2013
25. Liao, D. et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine 7, 665-673 (2011
26. Edgington, L. E. et al. Functional imaging of legumain in cancer using a new quenched activity-based probe. J. Am. Chem. Soc. 135, 174-182 (2013
27. Liu, Y., Bajjuri, K. M., Liu, C. & Sinha, S. C. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain proteaseactivated auristatin prodrug. Mol. Pharm. 9, 168-175 (2012
28. Bajjuri, K. M., Liu, Y., Liu, C. & Sinha, S. C. The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. ChemMedChem 6, 54-59 (2011
29. Wu, W. et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 66, 970-980 (2006 (Pubitemid 43165965)
30. Stern, L. et al. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug. Chem. 20, 500-510 (2009
31. Deshpande, P. P., Biswas, S. & Torchilin, V. P. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 8, 1323-1342 (2013
32. Sawant, R. R. & Torchilin, V. P. Design and synthesis of novel functional lipid-based bioconjugates for drug delivery and other applications. Methods Mol. Biol. 751, 357-378 (2011
33. Torchilin, V. P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90, 604-610 (2008
34. Kaplan, I. M., Wadia, J. S. & Dowdy, S. F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control. Release 102, 247-253 (2005 (Pubitemid 40093789)
35. Chen, S. et al. SOX2 regulates apoptosis through MAP4K4-Survivin signaling pathway in human lung cancer cells. Carcinogenesis 14, 14 (2013
36. Liu, Z. et al. Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice. PLoS ONE 8, e60190 (2013
37. Niestroj, A. J. et al. Inhibition of mammalian legumain by Michael acceptors and AzaAsn-halomethylketones. Biol. Chem. 383, 1205-1214 (2002 (Pubitemid 35215069)
38. Ekici, O. D. et al. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases. J. Med. Chem. 47, 1889-1892 (2004 (Pubitemid 38453908)
39. Murphy, E. A. et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA 105, 9343-9348 (2008
40. Gotz, M. G. et al. Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens. J. Med. Chem. 51, 2816-2832 (2008 (Pubitemid 351620803)
41. Ekici, O. D. et al. Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2,-3,-6,-7,-8,- 9, and-10. J. Med. Chem. 49, 5728-5749 (2006 (Pubitemid 44423710)
42. Ovat, A. et al. Aza-peptidyl Michael acceptor and epoxide inhibitors-potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases). J. Med. Chem. 52, 7192-7210 (2009).